Home
Oligonucleotide Therapeutics and Delivery
22 September - 23 September 2021

If you have registered for this conference, please click this link to login and join. Your login details should have been sent to you by portal@smi-online.co.uk

Post event on demand access to recorded presentations will be available to all attendees 5 working days from the end date of the event.

Oligonucleotide Therapeutics and Delivery

The SAE Media Group is proud to announce the
Oligonucleotide Therapeutics and Delivery Conference
22nd - 23rd September, 2021 | Virtual Conference | All Timings are BST
--------------------------------------------------------------------------------------------------

Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.

SAE Media Group’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions.
 

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

FEATURED SPEAKERS

Adrien Weingartner

Adrien Weingartner

Principal Scientist, Group Leader Drug Delivery, Silence Therapeutics AG
Amotz Shemi

Amotz Shemi

CEO, Silenseed
Andre  Muller-York

Andre Muller-York

Senior Medical Affairs Director, Sarepta Therapeutics Germany GmbH
Arthur A Levin

Arthur A Levin

Chief Scientific Officer, Avidity Biosciences Inc
Maria Luisa Pineda

Maria Luisa Pineda

CEO and Co-founder, Envisagenics
Martin Kerr

Martin Kerr

Head of Business Development & Partnerships, Nucleic Acid Therapy Accelerator
Meiling LI

Meiling LI

Senior Scientist , F. Hoffmann-La Roche Ltd.
Nagy Habib

Nagy Habib

Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
Patrick Endres

Patrick Endres

Junior Manager Application Development, Tosoh Bioscience GmbH
Samantha Sarett

Samantha Sarett

Research Engineer, Eli Lilly
Stefan Vonhoff

Stefan Vonhoff

VP Chemistry&Manufacturing, NOXXON Pharma AG
Tom Baladi

Tom Baladi

Postdoctoral Research Fellow, AstraZeneca
Wael Jdey

Wael Jdey

Head of Biology, Onxeo S.A.

Adrien Weingartner

Principal Scientist, Group Leader Drug Delivery, Silence Therapeutics AG
Adrien Weingartner

I studied Biophysics at Humboldt-University of Berlin and received my diploma in 2005.
During my PhD thesis at Humboldt-University I investigated the plasma membrane lipid asymmetry of a protozoan parasite and its impact on host cell invasion.
Following, I was working as a postdoctoral researcher on viral infection, gene regulation and immune cell aging at Helmholtz Centre for Infection Research.
In 2013 I joined Silence Therapeutics and since that time I am studying RNA delivery systems in vivo application.
 

Alexey Wolfson

CEO, Advirna
Alexey Wolfson

Amotz Shemi

CEO, Silenseed
Amotz Shemi

Andre Muller-York

Senior Medical Affairs Director, Sarepta Therapeutics Germany GmbH
Andre  Muller-York

Dr. André Müller-York obtained his MD from the Medical School of the University of Hamburg (Germany) and his board certification in nuclear medicine from the Charité at the University of Berlin. He joined the pharmaceutical industry at Amersham Health (now GE Healthcare) leading the clinical development of a cardiac MRI contrast media in EU and US. Later on, André supported several international companies for medical affairs in various indications, e.g. virology and neurology. Focused on orphan drugs and neuromuscular diseases during the last five years, he is now representing the medical affairs department of Sarepta Therapeutics (HQ: Cambridge, MA, USA) as a Sr. Medical Director in DACH, CEE and Russia. Starting with the development of phosphorodiamidate morpholino oligomers (PMOs), a subclass of antisense oligonucleotides (ASOs) for exon-skipping in Duchenne Muscular Dystrophy, the company is now also focusing on the development of AAV-based gene therapies for several neuromuscular diseases.

Arthur A Levin

Chief Scientific Officer, Avidity Biosciences Inc
Arthur A Levin

Arthur Levin is a leader in RNA therapeutics field. He serves as CSO at Avidity Biosciences. Previously, he held Senior level positions at mRiragen, Santaris Pharma, and Ionis Pharmaceuticals. He played key roles in developing numerous oligonucleotides including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He has three decades of experience in drug development from discovery through drug registration. Dr. Levin has published over 60 scientific articles, including highly cited reviews. He is on the scientific advisory boards of multiple institutions. Art received a doctorate in toxicology from the University of Rochester.

David Evans

Chief Scientific Officer, Sirnaomics, Inc
David Evans

Dr. Evans obtained his BSc and PhD from Imperial College, London. Over the last 3 decades he has built scientific research teams focused on target validation, drug discovery and high throughput screening of small molecule and siRNA libraries to identify lead candidates for development in Oncology and other indications. David has more than 15 years’ experience in the RNAi field – building genome scale screening capabilities for target identification in Oncology and other indications at TGEN and Dharmacon prior to cofounding Sirnaomics to focus on developing siRNA as a therapeutic. David previously worked at the Frederick National Lab for Cancer Research and in the Boston area with Millennium Pharmaceuticals and Serono Pharmaceuticals.

Ekkehard Leberer

Senior Consultant, ELBIOCON
Ekkehard Leberer

Dr. Leberer received his Ph.D. in Biology at the University of Konstanz, Germany (1986), and conducted post-doctoral training in molecular biology at the Banting and Best Institute of the University of Toronto, Canada. He then obtained the Habilitation for Professor of Biochemistry at the University of Konstanz, Germany (1992). From 1989-1998, he served as Senior Research Officer in genetics and genomics at the Biotechnology Research Institute, National Research Council of Canada, Montreal. He was also Adjunct Professor at McGill University, Montreal.
Since joining Hoechst Marion Roussel in 1998, Dr. Leberer carried out various managing roles in this company, Sanofi’s predecessor companies and Sanofi itself, including responsibilities in functional genomics, biological sciences, and external innovation and alliance management for oligonucleotide-based therapeutics. In addition, from 2012-2018, he has been the Scientific Managing Director of the Innovative Medicines Initiative COMPACT Consortium on the delivery of biopharmaceuticals across biological barriers and cellular membranes, Brussels. In 2021, he has founded Elbiocon (www.elbiocon.com) to provide consulting services in life sciences. He serves as a member in Scientific Advisory Boards of several biotechnology companies, and he is the Head of the Supervisory Board of BioM, Munich.
His research has focused on the molecular mechanisms of signal transduction and the role of signalling molecules in human diseases. He is the co-discoverer of the p21 activated protein kinase (PAK) family of cell signalling proteins and of novel virulence-inducing genes in pathogenic fungi. He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.
 

Guy Hermans

Chief Executive Officer, Sapreme Technologies B.V.
Guy Hermans

Guy joined Sapreme as CEO in 2020. He brings in over 15 years of experience in antibody fragment discovery and early development, as well as antibody discovery technology development.
In his previous position as CSO at Isogenica Ltd., he led internal technology and product development, as well as drive the scientific interactions with licensees and other partners. The re-engineering of the company and its product portfolio allowed it to become consistently profitable, and multiple leads discovered there have now entered the clinic.
Prior to this, Guy was Research Fellow at Ablynx where he conceived of many of its internal drug development programs and led a number of them through preclinical development. He was also responsible for several technology development programs, addressing challenging target classes or enabling novel applications for domain antibodies.
During his academic training, Guy did research in the pathogenesis and immunotherapy of autoimmune and inflammatory disorders, ranging from cell-based immunotherapy clinical trials in Multiple Sclerosis patients to target discovery and validation work at Stanford University Medical School.
 

Jon Voutila

Senior Research Scientist, MiNa Therapeutics Ltd
Jon Voutila

Maria Luisa Pineda

CEO and Co-founder, Envisagenics
Maria Luisa Pineda

Dr. Maria Luisa Pineda is the co-founder and CEO of Envisagenics, Inc. a biotech spinout of Cold Spring Harbor Laboratory that integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific splicing variants as therapeutic targets. Envisagenics has leveraged its SpliceCore® software platform for therapeutic development with its first pipeline of assets in triple negative breast cancer. Dr. Pineda received her PhD from the prestigious Watson School of Biological Sciences at Cold Spring Harbor Laboratory, then she acquired investment experience in technology and life-science startup companies at Canrock Ventures and Golden Seeds, LLC. Under Dr. Pineda’s leadership, Envisagenics has acquired nearly $2.5M in funding from the National Institutes of Health Small Business Innovation Research (SBIR) program and pre-seed investments from Topspin Partners and the Long Island Emerging Technology Fund, and from Breakout Labs, a Peter Thiel foundation. Envisagenics has raised over $5M from investors including Third Kind Venture Capital (3KVC), Cosine, LLC (NYC biotech investors), Dolby Family Ventures, Dynamk Capital, Madrona Venture Group, M12, NY Empire State Development (ESD), and SV Angel. Envisagenics has won several prestigious competitions such as the JLABS Artificial Intelligence for Drug Discovery QuickFire Challenge and was named the North American Winner of the Innovate.AI competition. More recently, Dr. Pineda secured Envisagenics’ first oncology partnership with a large pharmaceutical company. Dr. Pineda was named one of the top 20 Latinas in NYC by El Diario, NYC’s oldest Spanish Language newspaper and is an alumna of the Stanford Latino Entrepreneur Leaders Program developed by the Latino Business Action Network and the Stanford Graduate School of Business.

Martin Akerman

CTO & Co-Founder, Envisagenics
Martin Akerman

Martin Kerr

Head of Business Development & Partnerships, Nucleic Acid Therapy Accelerator
Martin Kerr

Martin Kerr joined the Nucleic Acid Therapy Accelerator, NATA, as Head of Business Development & Partnerships in June 2021, having spent the previous 15 years at the University of Oxford, initially as a researcher, before moving into business development for medical sciences with a particular focus on building strength in rare diseases. He holds a BSc in Cell Biology and a PhD in Molecular Genetics, both from the University of Glasgow, and then spent 4 years as a postdoctoral research associate at the MRC Laboratory of Molecular Biology in Cambridge before moving to Oxford.

Matthew Catley

Research Director, MiNa Therapeutics Ltd
Matthew Catley

Dr Matthew Catley completed his PhD studies of airway signalling pathways involved in lung disease with Peter Barnes at Imperial college. He completed further post-doctoral studies on the pharmacology of inhaled therapeutics with Maria Belvisi at Imperial College. Moving to UCB/Celltech he worked on monoclonal antibodies for the treatment of autoimmune and inflammatory disorders. In 2012 he moved to AstraZeneca in Gothenburg to help establish and run the preclinical bioscience department. After a year at Covance, Matthew Joined MiNA therapeutics in 2019 as Research Director. Matthew has developed a range of therapeutic modalities including small molecules, antibodies, peptides and oligonucleotides.

Meiling LI

Senior Scientist , F. Hoffmann-La Roche Ltd.
Meiling LI

Dr. Meiling Li is currently working as a senior scientist in RNA therapeutics in Hoffmann La Roche, Basel, Switzerland. Her research focuses on the modifications of the backbones in terms of stereodefined phosphorothioates, phosphorodithioates and other highly interested modifications. Dr. Li received her PhD from University of Oxford (UK) in organic synthetic chemistry. She then worked at ETH Zurich as a postdoc on nucleoside chemistry. In 2017 she moved to Hoffmann La Roche as a scientist in RNA therapeutics research department. Dr. Li has been involved in different projects of drug development and contributed greatly to the understanding of structure activity relationship (SAR) of oligonucleotide drugs.

Michel Janicot

CDO, InteRNA Technologies BV
Michel Janicot

Michel holds a Ph.D. degree in Biochemistry (Paris VII. France) and was Postdoctoral Fellow in the Dept. of Biological Chemistry (M. Daniel Lane) at The Johns Hopkins University (Baltimore, MD. USA). He has over 25-years hands-on experience in Oncology preclinical and early clinical pharmaceutical drug development in increasing leadership and managerial roles at Rhone-Poulenc Rorer (Sanofi) and subsequently, at Janssen (Johnson & Johnson). Since 2012, Michel is the founder and Managing Director of JMi ONConsulting, a Brussels-based consulting firm specialized in providing services and guidances for research and development programs in Oncology, Inflammation, Immunology, Vaccines, COPD, MS, Diabetes, Fibrosis and Ophthalmology

Nagy Habib

Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London
Nagy Habib

Nagy Habib is a leading translational researcher on liver cancer and its treatment. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He is the first person in the West to publish a clinical trial on the use of adult bone marrow derived stem cells for the treatment of patients with liver insufficiency.

He has published on the evolution of molecular biology of tumours from oncogene, tumour suppressor gene, epigenetic modification, gene therapy, stem cell therapy, RNA (Ribonucleic acid) and saRNA (small activating RNA) and RNA aptamers.

He is the inventor of, and was co-author of the first publication about the use for radiofrequency in devices used in liver surgery (Habib™ 4X), as well as interventional endoscopy (Habib™ EndoHPB – HPB: Hepatopancreatobiliary) and interventional radiology (Habib™ Percutaneous HPB, Habib™ VesCoag, Habib™ VesOpen).

Nagy is currently Lead Clinician and Head of the Department of HPB Surgery at Imperial College London. In June 2007 he was also appointed Pro Rector for Commercial Affairs at the university. He holds a gold award from the Advisory Committee for Clinical Excellence, which is given in recognition of exceptional contributions from NHS consultants, and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine. In December 2012, he was awarded the TAKREEM AWARD for Science and Technology for scientific work in liver cancer and the technological development of the Habib 4X surgical device. In 2015, Nagy was awarded a Foreign Membership of the prestigious French Académie Nationale de Chirurgie.
 

Patrick Endres

Junior Manager Application Development, Tosoh Bioscience GmbH
Patrick Endres

Patrick holds a M.Sc. degree in Bio-Engineering from the Karlsruhe Institute of Technology. He first joined Tosoh Bioscience in 2014 and is currently heading the european application development group, responsible for chromatographic application development and benchmarking of Tosoh Bioscience’s process resins, HPLC and UHPLC columns, as well as detectors. He authored multiple application notes and scientific papers and regularly presents his work to scientist and customers, aswell as at international conferences.

Samantha Sarett

Research Engineer, Eli Lilly
Samantha Sarett

Samantha Sarett is a Research Engineer with a decade of experience in nucleic acid delivery and formulation design. She received her PhD from Vanderbilt University, working in Dr. Craig Duvall’s lab on the design of several effective strategies for local or systemic delivery of small interfering RNA (siRNA). As a postdoctoral researcher at AbbVie, she focused on nanoparticle-mediated delivery of unconventional small molecule drugs. As a Senior Scientist at the Chicago-based biotechnology company Exicure, Samantha returned to the field of nucleic acid delivery, leading work on optimization and innovation of the spherical nucleic acid (SNA) nanoparticle formulation. Here, she focused on the particular challenge of delivery to the central nervous system CNS as well as the high unmet need in that scientific space.
In her current role in the New Therapeutic Modalities group at Eli Lilly, Samantha is driving the investigation and development of breakthrough nucleic acid delivery approaches to the CNS.

Stefan Vonhoff

VP Chemistry&Manufacturing, NOXXON Pharma AG
Stefan Vonhoff

Stefan Vonhoff, Ph.D. is VP Chemistry&Manufacturing at NOXXON Pharma AG, Berlin, Germany, a biotech company developing Spiegelmers – enantiomeric aptamers – for various therapeutic indications in the oncology area.
Stefan holds a Ph.D. in chemistry from University College London and received post-doctoral training in the Department of Chemistry at the ETH Zurich. He joined NOXXON in 1999 to establish the manufacturing process for L-nucleoside phosphoramidites and pegylated L-RNA aptamers. Today, his main responsibility is to coordinate external manufacturing and QC/QP-release activities for starting materials, drug substance, parenteral drug product and clinical trial supply.
 

Steve Pascolo

Founder and CEO, Miescher Pharma GmbH
Steve Pascolo

Trained as an immunologist at the Pasteur Institute (Paris, France), I used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during my post-doc in Tuebingen, Germany. In 1999, I co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. I was CSO of the company from 2000 till 2006, developing the technology, implementing the worldwide first GMP production of mRNA and performing the worldwide first clinical studies where humans got injections of in vitro transcribed mRNA. In 2006 I joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008 I founded Miescher Pharma to support this work. In 2017, we implemented in Zurich an mRNA platform https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html. In collaboration with several research and clinical departments in Zurich we test different mRNAs capable to enhance immunity against cancer. In addition, we developed modified RNA oligonucleotides to perform immunochemotherapies.

Tom Baladi

Postdoctoral Research Fellow, AstraZeneca
Tom Baladi

Tom Baladi was awarded his Ph.D. in Medicinal Chemistry in 2016 following his work on the design and development of selective small molecule kinase inhibitors at the Paris-Saclay University. For his second post-doctoral fellowship, he joined in 2018 the Wilhelmsson research group at Chalmers University (Gothenburg, Sweden) as part of the FoRmulaEx platform, a Swedish industry/academia consortium. He now focuses on the synthesis of fluorescent nucleobase analogs and their incorporation into various nucleotide-based modalities for in vitro imaging, to enable studies of drug-delivery systems. His work is performed at AstraZeneca Gothenburg, another active member of FoRmulaEx.

Wael Jdey

Head of Biology, Onxeo S.A.
Wael Jdey

As a scientist with an interest in health and disease, in particularly cancer, I aim to contribute to the understanding and targeting of this complex disease. My background in oncology, cell biology, signaling pathways and DNA repair showed me that interdisciplinary knowledge is the key in tackling complex diseases such cancer; Inter-group collaboration and team work are definitely key components to success. I am always looking to evolve in a stimulating environment where my skills and interdisciplinary knowledge can participate in the development of solutions for a medical unmet need to improve patient life quality.

sponsors

Conference agenda

clock

8:00

Registration & Coffee

clock

9:00

Chair's Opening Remarks

Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

clock

9:10

Immunochemotherapeutic oligonucleotides for cancer treatment

Steve Pascolo, Founder and CEO, Miescher Pharma GmbH

• Introducing the immunochemotherapeutic oligonucleotide approach
• Highlighting success in oncology mouse models to date
• Addressing challenges of delivery and maximising the EPR effect
• Vaccination with RNA
• Discussing next steps of the programs and evaluating potential delivery solutions
 

clock

9:45

The UK Nucleic Acid Therapy Accelerator (NATA)

• A background and introduction to the aims of the NATA in supporting the development of synthetic RNA therapeutics
• The NATA Hub: a world leading research institute to support the RNA therapeutics community, providing dedicated capability in oligo synthesis and biological screening
• The NATA’s upcoming funding calls to address barriers in the manufacture and the delivery of RNA therapeutics
• Opportunities to partner with the NATA Hub; Q&A session
 

Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy Accelerator

clock

10:20

Morning Coffee

clock

11:25

Introduction of non-chiral phosphorodithioates into Locked Nucleic Acids

Meiling LI, Senior Scientist , F. Hoffmann-La Roche Ltd.

• RNA therapeutics have clearly demonstrated their medical benefit.
• Phosphorothioates have been extensively profiled and cover most of the clinically investigated entities.The complexity of diastereoisomers have resulted in the great challenges in understanding PK/PD of stereomixed oligonucleotides.
• Introduction of non-chiral phosphorodithioates dramatically reduces the diastereomeric complexity and can potentially improve PK/PD of oligonucleotides.
• Combinations of phosphorodithioates and stereodefined motives will allow to rapidly identify highly potent one single phosphorothioate LNA isomer, which is supported by recent in vitro and in vivo data.
 

clock

12:00

Fluorescent Base Analogs (FBAs) in Gapmer Technology: Stealth Labeling of Antisense

Tom Baladi, Postdoctoral Research Fellow, AstraZeneca

• Outline of the design and assets of FBAs: modifying nucleobases to gain fluorescence properties without using external dyes
• Synthesis of FBA phosphoramidites and incorporation into ASOs
• Synthesis of FBA triphosphates and enzymatic incorporation into mRNA
• Assessment of structural, biological and photophysical properties of labelled constructs.
 

clock

12:35

Networking Lunch

clock

13:25

Formulation strategies for the development of injectable Spiegelmer drug product solutions

Stefan Vonhoff, VP Chemistry&Manufacturing, NOXXON Pharma AG

• Introducing the Spiegelmer technology approach and NOXXON’s clinical development program
• Defining a target product profile for injectable Spiegelmer drug product solutions
• Overcoming development challenges for Spiegelmers drug product solutions
• Establishing quality control methods for Spiegelmer drug product manufacturing and release in accordance with guidelines
 

clock

14:10

How to purify and analyse Oligonucleotide APIs

Patrick Endres, Junior Manager Application Development, Tosoh Bioscience GmbH

  • Introducing chromatographic approaches for purification and analysis
  • Choosing appropriate strategies for different impurity classes
  • Selected examples for the purification and analysis of therapeutic oligonucleotides
  • clock

    14:50

    Evolution, challenges and potential of RNA Therapeutics

    Samantha Sarett, Research Engineer, Eli Lilly

    • Background on RNA Therapeutics –what it encompasses, current
    status and pipeline
    • Challenges surrounding development of RNA Therapeutics
    • Promising future of RNA therapeutics
     

    clock

    15:25

    Afternoon Tea

    clock

    15:55

    Case study: Automating the discovery and development of RNA therapeutics

    Maria Luisa Pineda, CEO and Co-founder, Envisagenics

    • Envisagenics’ SpliceCore platform integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific isoforms that will function as therapeutic targets
    • Proof-of-concept program in Triple Negative Breast Cancer (TNBC) – discovery of TNBC specific splicing isoforms
    • Machine learning driven methodologies to designing and developing RNA therapeutics targeting TNBC specific splicing isoforms
    • Streamlined experimental validations of SpliceCore designed RNA therapeutics
     

    clock

    16:30

    Treating diseases with antibody oligonucleotide conjugates: Combining the selectivity of antibodies with the specificity of oligonucleotide drugs

    • Antibody oligonucleotide conjugates utilize the selectivity of antibody delivery and the specificity of oligonucleotide therapeutics to treat diseases
    • AOC1001 is designed to treat myotonic dystrophy type 1
    • Other AOCs are in development to address muscle disease and other disorders
     

    Arthur A Levin, Chief Scientific Officer, Avidity Biosciences Inc

    clock

    17:05

    Chair’s Closing Remarks and Close of Day One

    Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chair's Opening Remarks

    Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

    clock

    9:10

    The tool-box approach to improve the performance of siRNA-platform technology

    Adrien Weingartner, Principal Scientist, Group Leader Drug Delivery, Silence Therapeutics AG

    • Interplay of design and function
    • Stability and duration of action
    • Linker design and valency of ligands
    • Is there room for additional improvements?
     

    clock

    9:45

    Recent clinical progress with RNAi loaded KRAS-LODER for pancreatic tumour

    Amotz Shemi

    Amotz Shemi, CEO, Silenseed

    • Introducing the RNAi loaded KRAS-LODER for targeting KRAS mutations
    • Overviewing recent clinical success in phase II trials
    • Presenting phase II clinical trials results including primary and secondary endpoints
    • Outlining next steps of programme

    clock

    10:20

    Morning Coffee

    clock

    10:50

    INT-1B3 (miR-193a-3p mimic): from bench-to-bedside

    Michel Janicot, CDO, InteRNA Technologies BV

    • Focus on microRNA R&D
    • Success (bench-to-bedside) story for Oncology therapeutic intervention
    • Preclinical to first in human study transition
     

    clock

    11:25

    Targeted Delivery of C/EBPa-saRNA by RNA Aptamers

    Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

    • Understanding the principles of RNA activation and possibilities of therapeutic benefit
    • Harnessing small activating RNAs for the treatment of Pancreatic ductal adenocarcinoma
    • Evaluating aptamers and appropriate means of targeted delivery
    • Looking at lessons learnt from using saRNA for oncological purposes
     

    clock

    12:00

    Networking Lunch

    clock

    13:00

    Targeted cytoplasmic delivery of oligonucleotides

    Guy Hermans, Chief Executive Officer, Sapreme Technologies B.V.

    • Sapreme’s SPT001 compound improves cellular delivery of non-permeable biomolecules such as nucleic acids by up to 1000 fold by enhancing their escape from the endosome
    • SPT001 conjugation to a targeting ligand can drive payload internalization and cytoplasmic delivery in a cell- or tissue specific manner – further improving the therapeutic window of any given antisense oligo or siRNA
    • We will highlight recent proof-of-principle studies on nucleic acid delivery in vitro and in vivo
     

    clock

    13:35

    MicroRNA Therapeutics: Targeting the Pathways of Human Disease

  • MicroRNAs are short non-coding RNAs that regulate biochemical pathways by RNA interference (RNAi) Dysregulation of microRNAs is associated with many diseases
  • MicroRNA-21 has been implicated with fibrotic diseases and cancer
  • The presentation shows the development of anti-fibrotic and anti-cancer therapeutic strategies using anti-miRs as therapeutic molecules
  •  

    Ekkehard Leberer, Senior Consultant, ELBIOCON

    clock

    14:10

    Afternoon Tea

    clock

    14:40

    Delivery of Novel siRNA constructs for treating cancer

    David Evans, Chief Scientific Officer, Sirnaomics, Inc

    • Creating siRNA payloads for cancer treatment
    • Understanding the challenges of cell-specific delivery: how to get size and efficacy right?
    • Choosing the appropriate delivery system
    • Presenting success and future steps

    clock

    15:15

    Chair’s Closing Remarks and Close of Day Two

    Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London


    Principal Scientist, Group Leader Drug Delivery
    Silence Therapeutics AG
    CEO
    Advirna
    CEO
    Silenseed
    Senior Medical Affairs Director
    Sarepta Therapeutics Germany GmbH
    Chief Scientific Officer
    Avidity Biosciences Inc
    Chief Scientific Officer
    Sirnaomics, Inc
    Senior Consultant
    ELBIOCON
    Chief Executive Officer
    Sapreme Technologies B.V.
    Senior Research Scientist
    MiNa Therapeutics Ltd
    CEO and Co-founder
    Envisagenics
    CTO & Co-Founder
    Envisagenics
    Head of Business Development & Partnerships
    Nucleic Acid Therapy Accelerator
    Research Director
    MiNa Therapeutics Ltd
    Senior Scientist
    F. Hoffmann-La Roche Ltd.
    CDO
    InteRNA Technologies BV
    Professor of Surgery, Imperial College, Co-founder MiNA therapeutics
    Imperial College London
    Junior Manager Application Development
    Tosoh Bioscience GmbH
    Research Engineer
    Eli Lilly
    VP Chemistry&Manufacturing
    NOXXON Pharma AG
    Founder and CEO
    Miescher Pharma GmbH
    Postdoctoral Research Fellow
    AstraZeneca
    Head of Biology
    Onxeo S.A.

    Exhibitors

    Official Media Partner

    Supporting Media Partners

    Preliminary Attendees 2021

    Download

    Speaker Interview with Patrick Endres, Tosoh Bioscience

    Download

    Speaker Interview - Nagy Habib, Imperial College London

    Download

    Speaker Interview - Amotz Shemi, Silenseed

    Download

    Past Attendees 2021

    Download

    Speaker interview with Martin Akerman, Envisagenics

    Download

    Speaker interview with STEVE PASCOLO, Miescher Pharma GmbH

    Download

    Short Programme 2021

    Download

    Speaker bio's 2021

    Download

    Workshop programme 2021

    Download

    Full programme 2021

    Download

    Brochure 2021

    Download

    Speaker Interview - Maria Luisa Pineda, Envisagenics

    Download

    RNA infographic

    Download

    David Blakey - MiNA therapeutics, Past presentation

    Download

    Christopher Bunker- Bio-techne, Past presentation

    Download

    Heinrich Haas - BioNTech, Past presentation

    Download

    Surender Vashist - AstraZeneca, Past presentation

    Download

    Ethris, Past presentation

    Download

    Dr Simon Newman - NanoGenics, Past presentation

    Download

    Davis C. Henchall - Future neuro, Past presentation

    Download

    Dr Kirsty Wydenbach - MHRA, Past presentation

    Download

    David Deutsch - MHRA, Past presentation

    Download

    Bo Rode Hansen - GENEVANT, Past presenation

    Download

    Dr. Michel Janicot - InteRNA Technologies, Past presentation

    Download

    Exhibitors


    ChemGenes

    Exhibitors
    http://www.chemgenes.com

    ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.


    GenScript

    Exhibitors
    https://www.genscript.com/

    GenScript is a world leader in biotechnology reagent services, providing life sciences services and products to over 200,000 scientists in over 100 countries worldwide. Established in 2002 in New Jersey, United States, the company was one of the first to commercialize gene synthesis as well as establish fully integrated capabilities for custom peptide synthesis, complex protein expression and engineering, custom antibody development and engineering, in vitro/in vivo pharmacology, as well as a variety of other research-focused catalogue products.

    After almost two decades of rapid growth, the company has expanded its business in recent years into the fields of immunotherapy, CDMO and microbiology to further its core mission of making people and nature healthier through biotechnological innovation.

    With global support from its loyal customers and over 2600 employees located across the globe, GenScript continues to strive towards their vision of being the most reliable biotech company in the world, in service of a better and healthier future.



    Tosoh Bioscience

    Exhibitors
    https://www.tosohbioscience.com/

    Tosoh Bioscience is an acknowledged global leader in liquid chromatography with a focus on bioseparations. Our team of chromatography experts enables our biopharma partners to provide safe and efficient therapies against life threatening diseases. Our portfolio encompasses SEC instruments and a comprehensive line of media and process development, HPLC, and UHPLC columns. The products are used in R & D, process development, downstream processing, and quality control of biologics, biosimilars or biobetters. Typical applications comprise the purification of therapeutic proteins and oligonucleotides at lab, pilot, and commercial scale, as well as their characterization and QC analysis by (U)HPLC. Tosoh Bioscience is part of the Tosoh Group, a Japanese chemical and specialty products group with over 100 companies worldwide and a workforce of about 13000 people.

    Media Partners


    Pharma Journalist

    Official Media Partner
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

    Media Partners


    Pharmacircle

    Supporting Media Partners
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Contract Biotechnology

    Supporting Media Partners
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    ASD MEDIA

    Supporting Media Partners
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    Gene Therapy Net

    Supporting Media Partners
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


    Pharmaceutical Technology

    Supporting Media Partners
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    pharmaphorum

    Supporting Media Partners
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Drug Discovery Today

    Supporting Media Partners
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Pharmalicensing

    Supporting Media Partners
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    World Pharma News

    Supporting Media Partners
    http://www.worldpharmanews.com/



    SciDoc Publishers

    Supporting Media Partners
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Technology Networks

    Supporting Media Partners
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Farmavita

    Supporting Media Partners
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.